


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound represented by formula (I)



wherein ~~—~~ is a single bond or a double bond,


~~—~~ is α -configuration, β -configuration or a voluntary mixture of α -configuration and β -configuration,

D is -COOR¹ or tetrazoyl,

R¹ is hydrogen or C1-4 alkyl,

G is ringA or C1-4 alkylene,

ringA is



R² is a halogen atom, C1-4 alkyl or C1-4 alkoxy,

p is 0 or an integer of 1-4,


when p is 2 or more, plural R³'s are the same or different;

Y is a single bond or -S-,

T is oxygen or sulfur,

X is -CH₂-, -O- or -S-,

ringB is C3-7 cycloalkyl optionally substituted,



wherein R³ is (1) a halogen atom, (2) C1-4 alkyl optionally substituted with 1-5 of halogen atom(s), (3) C1-4 alkoxy optionally substituted with 1-5 of halogen atom(s), (4) C1-4 alkyl substituted with C1-4 alkoxy, (5) phenyl or (6) 3- to 15- membered mono-, bi- or tri-heterocyclic aryl containing 1 to 4 hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulfur atom(s) which may be partially or fully saturated, and (5) phenyl or (6) heterocyclic aryl in R³ is optionally substituted with 1-3 of (a) halogen atom(s), (b) C1-4 alkyl, (c) C1-4 alkoxy and/or (d) nitro,

q is 0 or an integer of 1-5,


when q is 2 or more, plural R³'s are the same or different, and

n is an integer of 1-4,

a salt thereof, a solvate thereof, a cyclodextrin clathrate thereof, or a prodrug thereof.


2. (canceled).

3. (currently amended): The compound according to claim 1, which is represented by formula (I-1):




wherein G¹ is ringA¹ or C1-4 alkylene,

ringA¹ is



wherein left-pointing arrow represents binding to S, and right-pointing arrow represents binding to COOR¹,

ringB¹ is C3-7 cycloalkyl,



ringB¹ may be substituted with a halogen atom, C1-4 alkyl, phenyl, methoxymethyl, trifluoromethyl and/or trifluoromethoxy,

other symbols have the same meanings as described in claim 1, and

wherein when T is oxygen, X is -CH₂- , and

when n is an integer of 2-4, G¹ is ringA¹.

4. (currently amended): The compound according to claim 3, which is selected from the group consisting of:

- (1) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-phenylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid;
- (2) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid;
- (3) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-chloro-4-fluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid;
- (4) (15 α ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid;
- (5) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid;
- (6) (15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3-phenylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid;
- (7) (15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3-methylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid;
- (8) (15 α ,13E)-9-oxo-15-hydroxy-16-(3,5-difluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid;
- (9) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-fluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-exaprostan-13-enoic acid,


- (10) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3-trifluoromethylphenyl)-17,18,19,20-tetraenol-5-thia-8-aza-10-oxaprostan-13-enoic acid;~~
- (11) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-trifluoromethylphenyl)-17,18,19,20-tetraenol-5-thia-8-aza-10-oxaprostan-13-enoic acid;~~
- (12) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3,4-difluorophenyl)-17,18,19,20-tetraenol-5-thia-8-aza-10-oxaprostan-13-enoic acid;~~
- (13) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-phenyl-17,18,19,20-tetraenol-5-thia-8-aza-10-oxaprostan-13-enoic acid;~~
- (14) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-propylphenyl)-17,18,19,20-tetraenol-5-thia-8-aza-10-oxaprostan-13-enoic acid;~~
- (15) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-methoxymethylphenyl)-17,18,19,20-tetraenol-5-thia-8-aza-10-oxaprostan-13-enoic acid;~~
- (16) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-ethyl-4-fluorophenyl)-17,18,19,20-tetraenol-5-thia-8-aza-10-oxaprostan-13-enoic acid;~~
- (17) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-phenyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octenol-5-thia-8-aza-10-oxaprostan-13-ene;~~
- (18) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-methylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octenol-5-thia-8-aza-10-oxaprostan-13-ene;~~
- (19) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octenol-5-thia-8-aza-10-oxaprostan-13-ene;~~

- (20) (15 α ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-azaprostan-13-ene;
- (21) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-phenylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-azaprostan-13-ene;
- (22) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-phenylphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene;
- (23) (15 α ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene;
- (24) (15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3-phenylphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene;
- (25) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene;
- (26) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-methylphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene;
- (27) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-5-(5-carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene;
- (28) (15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3-phenylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene;
- (29) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,


- (30) — (15 α ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (31) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (32) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-chloro-4-fluorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (33) — (15 α ,13E)-9-oxo-15-hydroxy-16-cyclopropyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (34) — (15 α ,13E)-9-oxo-15-hydroxy-16-cyclohexyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (35) (15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluorophenyl)-5-(5-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene, and
- (36) — (15 α ,13E)-9-oxo-15-hydroxy-16-cyclobutyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (37) (15 α ,13E)-9-oxo-15-hydroxy-16-(4-chlorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (38) — (15 α ,13E)-9-oxo-15-hydroxy-16-cycloheptyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (39) — (15 α ,13E)-9-oxo-15-hydroxy-16-(indane-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;

- (40) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(tetrahydropyran-4-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octenol-5-thia-8-azaprostan-13-ene,~~
- (41) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(7-methylnaphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octenol-5-thia-8-azaprostan-13-ene;~~
- (42) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluorophenyl)-17,18,19,20-tetranol-5,10-dithia-8-azaprostan-13-enoic acid,~~
- (43) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(4-fluorophenyl)-17,18,19,20-tetranol-6-thia-8-azaprostan-13-enoic acid;~~
- (44) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-methylphenyl)-17,18,19,20-tetranol-6-thia-8-azaprostan-13-enoic acid, and~~
- (45) ~~(15 α ,13E)-9-thioxo-15-hydroxy-16-(4-fluorophenyl)-17,18,19,20-tetranol-5-thia-8-azaprostan-13-enoic acid.~~

5. (currently amended): The compound according to claim 1, which is represented by formula (I-2):



wherein G² is



wherein left-pointing arrow represents binding to $-(CH_2)_2-$, and right-pointing arrow represents binding to D,

R^4 is (1) a halogen atom, (2) C1-4 alkyl, (3) C1-4 alkoxy, (4) C1-4 alkyl optionally substituted with 1-5 of halogen atom(s), (5) C1-4 alkoxy optionally substituted with 1-5 of halogen atom(s), (6) phenyl or (7) 3- to 15-membered mono-, bi- or tri-heterocyclic aryl containing 1 to 4 hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulfur atom(s) which may be partially or fully saturated, and (6) phenyl or (7) heterocyclic in the R^4 may be substituted with 1-3 of (a) a halogen atom(s), (b) C1-4 alkyl, (c) C1-4 alkoxy and/or (d) nitro,

r is an integer 1 to 5, and

other symbols have the same meanings as described in claim 1.

6. (currently amended): The compound according to claim 5, which is selected from the group consisting of:

- (1) (15 α ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3,5-dimethylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid;
- (2) (15 α ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(benzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid;

- (3) ——— (15 α ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(4-fluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid;
- (4) ——— (15 α ,13E)-9-oxo-15-hydroxy-16-(3-(5-methylbenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,
- (5) ——— (15 α ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(5-methylbenzoxazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (6) ——— (15 α ,13E)-9-oxo-15-hydroxy-16-(3-(6-methylbenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,
- (7) ——— (15 α ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(6-methylbenzoxazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (8) ——— (15 α ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(4-methylbenzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (9) ——— (15 α ,13E)-9-oxo-15-hydroxy-16-(3-(4-methylbenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,
- (10) ——— (15 α ,13E)-1,6-(2-fluoro-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (11) ——— (15 α ,13E)-1,6-(3-methyl-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprostan-13-enoic acid,
- (12) ——— (15 α ,13E)-9-oxo-15-hydroxy-16-(3-(5,7-dimethylbenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprostan-13-ene,

- (13) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (14) (15 α ,13E)-1,6-(1,4 interphenylene)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (15) (15 α)-9-oxo-15-hydroxy-16-(3-(2,4-dimethylphenyl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (16) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-(3,4-dimethylphenyl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene, and
- (17) (15 α ,13E)-1,6-(1,4 interphenylene)-9-oxo-15-hydroxy-16-(3,4 difluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (18) (15 α ,13E)-1,6-(2 methyl-1,4 interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (19) (15 α ,13E)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (20) (15 α ,13E)-1,6-(1,4 interphenylene)-9-oxo-15-hydroxy-16-(3 methyl-4-fluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (21) (15 α ,13E)-1,6-(1,4 interphenylene)-9-oxo-15-hydroxy-16-(3 chloro-4-fluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (22) (15 α ,13E)-1,6-(3 methoxy-1,4 interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

- (23) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-17,18,19,20-tetraenol-5-thia-8-azaprostan-13-enoic acid;~~
- (24) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3,5-difluorophenyl)-17,18,19,20-tetraenol-5-thia-8-azaprostan-13-enoic acid;~~
- (25) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-(phenyl)phenyl)-17,18,19,20-tetraenol-5-thia-8-azaprostan-13-enoic acid;~~
- (26) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-(4-fluorophenyl)phenyl)-17,18,19,20-tetraenol-5-thia-8-azaprostan-13-enoic acid, and~~
- (27) ~~(15 α ,13E)-9-oxo-15-hydroxy-16-(3-phenyl-4-fluorophenyl)-17,18,19,20-tetraenol-5-thia-8-azaprostan-13-enoic acid.~~

7. (previously presented): A pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof, a cyclodextrin clathrate thereof, or a prodrug thereof, and a pharmaceutically acceptable carrier.

8-10. (canceled).

11. (previously presented): The compound according to claim 1, wherein n is 1 or 2.